We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Venn Life Sciences Holdings Plc | LSE:VENN | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.85 | 6.70 | 7.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMSKIN TIDMVENN
RNS Number : 7383X
Integumen PLC
01 May 2019
AIM share code: SKIN
1 May 2019
Integumen PLC
("Integumen" or "Company")
Changes to interests of a significant shareholder
Integumen has received a notification of a change in the interests of a significant shareholder. In accordance with AIM Rule 17, the following details are now notified:
Following the approval of Integumen shareholders at yesterday's general meeting and under the terms of the Venn Debt Conversion Agreement (as defined in the Company's announcement of 12 April 2019) the debt of GBP421,000 owed by Integumen has been converted into 30,071,428 new Integumen ordinary shares at a price of 1.4 pence ("Debt Conversion Shares"), conditional upon admission. Admission is expected to take place at 8.00 a.m. on 2 May 2019.
Separate to this conversion, the Company has been advised that Venn Life Sciences Holdings plc ("Venn") has sold 42,244,682 ordinary shares for a total consideration of EUR575,000. Following Admission of the Debt Conversion Shares, Venn will hold 30,071,428 ordinary shares, representing 3.18% of the enlarged issued share capital .
Venn has agreed that any disposal of Integumen ordinary shares held by them for the two years following Admission will be effected through Integumen's broker so as to ensure an orderly market in the ordinary shares.
In compliance with DTR5, a copy of the notification received from this investor is appended below.
Hot Features
Premium
Integumen plc Gerard Brandon, CEO +44 (0) 7340 055 648
SPARK Advisory Partners
Limited Neil Baldwin/Vassil
(Nominated Adviser) Kirtchev +44 (0) 113 370 8974
--------------------- ---------------------
Turner Pope Investments
(TPI) Limited (Broker) Andy Thacker +44 (0) 20 3621 4120
--------------------- ---------------------
About Integumen:
Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.
The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and
to the FCA in Microsoft Word format if possible)(i)
1a. Identity of the issuer or the Integumen PLC
underlying issuer of existing shares
to which voting rights are attached(ii)
:
--------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
----
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights X
----
An acquisition or disposal of financial instruments
----
An event changing the breakdown of voting rights
----
Other (please specify)(iii) :
----
3. Details of person subject to the notification obligation(iv)
Name Venn Life Sciences Holdings plc
City and country of registered office London, United Kingdom
(if applicable)
4. Full name of shareholder(s) (if different from 3.)(v)
Name
--------------------------------------------
City and country of registered office
(if applicable)
--------------------------------------------
5. Date on which the threshold was 30/04/2019
crossed or reached(vi) :
--------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 01/01/2019
--------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting rights Total of both Total number
rights attached through financial in % (8.A + of voting rights
to shares (total instruments 8.B) of issuer(vii)
of 8. A) (total of 8.B
1 + 8.B 2)
------------------ --------------------- -------------- --------------------
Resulting situation Zero n/a Zero
on the date
on which threshold
was crossed
or reached Zero
------------------ --------------------- -------------- --------------------
Position of
previous notification
(if
applicable)
------------------ --------------------- -------------- --------------------
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached(viii)
A: Voting rights attached to shares
Class/type of Number of voting rights(ix) % of voting rights
shares
ISIN code (if
possible)
Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive
2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.1) (DTR5.2.1) (DTR5.2.1)
-----------------------------
GB00BYWJ6269 Zero n/a Zero n/a
------------------------ ----------------------------- ------------------------- ---------------------
SUBTOTAL 8. A Zero Zero
------------------------------------------------------- ------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Type of Expiration Exercise/ Number of voting % of voting
financial date(x) Conversion Period(xi) rights that may rights
instrument be acquired if
the instrument
is
exercised/converted.
----------- ----------------------------------- -------------------------------- ---------------------
n/a
----------- ----------------------------------- -------------------------------- ---------------------
SUBTOTAL 8. B 1
----------------------------------- -------------------------------- ---------------------
B 2: Financial Instruments with similar economic effect according to
Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical or Number of % of voting
financial date(x) Conversion cash voting rights rights
instrument Period (xi) settlement(xii)
--------------- ---------------------- ----------------------- --------------------
n/a
--------------- ---------------------- ----------------------- --------------------
SUBTOTAL 8.B.2
----------------------- --------------------
9. Information in relation to the person subject to the notification
obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled x
by any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer(xiii)
Full chain of controlled undertakings through which the voting rights
and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity(xiv) (please add additional
rows as necessary)
Name % of voting rights % of voting rights Total of both if
if it equals or through financial it equals or is
is higher than the instruments if it higher than the
notifiable threshold equals or is higher notifiable threshold
than the notifiable
threshold
---------------------- --------------------- ------------------------
n/a
---------------------- --------------------- ------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder n/a
-----------------------------------------------
The number and % of voting rights n/a
held
-----------------------------------------------
The date until which the voting rights n/a
will be held
-----------------------------------------------
11. Additional information
n/a
Place of completion London
Date of completion 01/05/2019
-----------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
HOLCKDDQCBKKFPK
(END) Dow Jones Newswires
May 01, 2019 06:00 ET (10:00 GMT)
1 Year Venn Life Sciences Chart |
1 Month Venn Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
